Table 5.
Summary of metabolic outcomes in clinical trials
|
Parameters
|
Ferguson et al[33], 2011 (25)
|
de Graav et al[34], 2017
|
Newell et al[35], 2017 (27)
|
Clinicaltrial.gov 1856257, 2017 (28)
|
||||
|
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
Gp1 (Belatacept)
|
Gp2 (Tacrolimus)
|
| Total CH, Mean (SD) (mg/dL) | NA | NA | 193.34 ± 42.43 | 187.41 ± 42.28 | 187.0 | 156.0 ± 30.4 | 163.7 ± 38.8 | 177.1 ± 25.6 |
| Total TG, Mean (SD) (mg/dL) | NA | NA | 194.86 ± 51.14 | 221 ± 127.87 | 187.0 | 319.3 ± 294.0 | 170.0 ± 118.6 | 125.8 ± 93.0 |
| LDL, Mean (SD) (mg/dL) | NA | NA | 64.78 ± 30.20 | 96.67 ± 55.84 | 114.0 | 69.5 ± 38.0 | 86.3 ± 50.6 | 102.9 ± 17.7 |
| BP mm/Hg (SBP/DBP) (12 mo) | 129.3 ± 19.24/73.3 ± 11.96 | 138.2 ± 19.50/77.6 ± 10.51 | 141.25 ± 14.75/74 .25 ± 8.75 | 142.5 ± 17.31/78.0 ± 13.0 | 146.7 ± 5.1/92.7 ± 9.8 | 147.5 ± 18.7/80.8 ± 12.8 | 133.7 ± 14.7/79.1 ± 10.2 | 135.0 ± 18.9/77.7 ± 10.9 |
Lipid parameters represented in mean change from baseline to month 12 post transplantation.